RobGenes
Holdings
AI-Powered Precision Health, Longevity & Molecular Personalization
From molecular data to clinical intelligence, personalized interventions and global recurring revenue.
RobGenes
Holdings
AI-Powered Precision Health, Longevity & Molecular Personalization
From molecular data to clinical intelligence, personalized interventions and global recurring revenue.
Not a test. A precision health operating system.
Most companies sell isolated genetic tests, supplements, reports or software. RobGenes connects all of these into one intelligent ecosystem.
- ●Molecular data becomes clinical intelligence
- ●Clinical intelligence becomes personalized intervention
- ●Personalized intervention creates recurring revenue
- ●Recurring revenue strengthens the holding company
- ●Each patient, clinic and partner increases platform value
Already commercial. Already scaling.
Founded in 2024 — and already generating revenue with elite clinical partners across the Middle East.
Precision health is fragmented.
A unified ecosystem for molecular personalization.
RobGenes Holdings integrates diagnostics, AI interpretation, clinical action, personalized products, physician education and international licensing into one scalable platform.
- ●Genomics · Methylation · Epigenetics
- ●Pharmacogenetics · Microbiome
- ●Biological Age · Blood Biomarkers
- ●Personalized Supplements
- ●Physician Academy · Concierge Longevity
- ●Global Master Licensing
The market timing is exceptional.
AI does not replace RobGenes. AI multiplies RobGenes.
- ✕General knowledge
- ✕No proprietary clinical workflow
- ✕No curated database
- ✕No integrated patient pathway
- ✕No supplement formulation system
- ✕No physician training network
- ✕No master licensing infrastructure
- ✓Structured molecular interpretation
- ✓Curated genomics & pathway logic
- ✓Personalized report generation
- ✓Genotype-guided supplement logic
- ✓Physician dashboard
- ✓Multi-omics integration
- ✓Country licensing & commercial engine
- ✓Continuously improving knowledge base
AI is the engine. RobGenes is the architecture, data model, clinical logic, product ecosystem, brand, distribution and commercialization layer.
A category of one.
RobGenes combines assets that are usually separated across different companies — into a five-layer integrated platform.
- ●L1 — Molecular Data: genetics, methylation, microbiome, biomarkers
- ●L2 — AI Clinical Intelligence: pathway analysis, risk scoring
- ●L3 — Actionable Products: supplements, protocols, age tracking
- ●L4 — Physician Adoption: training, dashboards, certification
- ●L5 — Global Scale: master licensees, distributors, clinic networks
Multiple verticals. One holding. One compounding ecosystem.
RobGenes Methylation Intelligence
Turning epigenetic signals into clinical action.
Transforms CpG-level data, hypermethylation, biological age acceleration, inflammation patterns, detox pressure, mitochondrial stress and hormone-related signatures into physician- and patient-friendly reports.
- ●Per-report fee
- ●Clinic subscription
- ●Lab white-label
- ●Annual methylation tracking
- ●API access
- ●Premium physician interpretation
RobGenes Genetic Supplements
From genetic insight to recurring personalized product revenue.
20+ genotype-guided formulas — COMT, MTHFR, MAOA, GST, APOE, HMGCR, PEMT, MTR/MTRR, BHMT, CBS, NOS3, BDNF and more.
- ●Direct-to-consumer
- ●Monthly subscriptions
- ●Clinic resale
- ●Practitioner kits
- ●International distribution
- ●Private-label formulas
RobAge Biological Age Intelligence
A measurable longevity platform.
Integrates biomarkers, genetics, methylation, lifestyle, inflammation, oxidative stress, metabolic and immune markers into a visual biological age and longevity roadmap.
- ●Biological age reports
- ●Annual tracking
- ●Longevity subscriptions
- ●Clinic dashboards
- ●Executive health plans
- ●Family office packages
RobGenes Pharmacogenetics
Personalizing medication decisions through genetic intelligence.
Helps physicians understand how genetic variants influence drug metabolism, side effect risk and therapeutic response.
- ●PGx reports
- ●Clinic dashboards
- ●Hospital licensing
- ●API access
- ●Medication-specific modules
- ●Enterprise integrations
RobGenes Microbiome Intelligence
Connecting gut ecology to personalized health strategies.
Diversity, dysbiosis, beneficial bacteria, pathogen patterns, gut inflammation, metabolic and immune relevance and gut-brain axis implications.
- ●Microbiome reports
- ●Gut health subscriptions
- ●Supplement recommendations
- ●Clinic dashboards
- ●AI follow-up
- ●Personalized protocols
RobGenes AI Clinical Intelligence Platform
The intelligence layer behind the entire ecosystem.
Connects genetics, methylation, biomarkers, microbiome, pharmacogenetics, lifestyle, supplements and clinical history into structured precision-health recommendations.
- ●SaaS subscriptions
- ●AI report credits
- ●API usage
- ●White-label reports
- ●Clinic dashboards
- ●Lab integration
- ●Enterprise licensing
RobGenes Physician Academy
Turning doctors into adoption channels.
Global education and certification for physicians, nutritionists, longevity specialists, wellness clinics and pharmacists.
- ●Online courses
- ●Certifications
- ●Live bootcamps
- ●Annual memberships
- ●Corporate training
- ●Country education licenses
RobGenes Concierge Longevity
Premium recurring health optimization.
Luxury health optimization combining testing, interpretation, home collection, personalized supplements, physician review and continuous follow-up.
- ●Annual executive plans
- ●Family office longevity
- ●Premium memberships
- ●Home sample collection
- ●Personalized supplement delivery
- ●VIP physician review
Global expansion without building everything ourselves.
Global demand is rising across key markets.
The RobGenes model is designed for international replication via master licensees, clinic networks, distributors, physician education and localized report delivery.
- ●UAE · Saudi Arabia · Qatar · Kuwait
- ●United Kingdom · United States · Portugal
- ●Brazil · Argentina · Ecuador
- ●Malaysia · Singapore · South Korea · India · China
- ●Australia · Greece · Turkey
A multi-market opportunity.
RobGenes operates at the intersection of the largest health-tech growth markets.
RobGenes operates at the intersection of seven of the fastest-growing health-tech and consumer-health markets globally.
Multiple revenue layers. One compounding platform.
The RobGenes compounding growth engine.
Each vertical strengthens the others. The more the ecosystem is used, the more valuable the platform becomes.
- ●More tests → more reports → more patient data
- ●Better AI interpretation → more supplement protocols
- ●More recurring revenue → more physicians trained
- ●More clinics & country partners → more global adoption
- ●Higher valuation → more capital → more expansion
A holding company built for scalable monetization.
RobGenes Holdings owns brand, IP, AI platform, report architecture, supplement logic, data infrastructure, education platform, licensing framework and global partner model.
- ●Product revenue
- ●SaaS revenue
- ●Licensing revenue
- ●Education revenue
- ●Subscription revenue
- ●Premium service revenue
Why RobGenes has no true direct competitor.
- ✕Genetic testing labs
- ✕Supplement brands
- ✕Longevity clinics
- ✕Microbiome companies
- ✕PGx labs
- ✕AI health tools
- ✕Education platforms
- ✓Multi-omics interpretation
- ✓AI clinical intelligence
- ✓Personalized supplement conversion
- ✓Physician academy
- ✓Biological age engine
- ✓International master licensing
- ✓Premium concierge model
- ✓Holding-company strategy
Competitors exist in individual categories. RobGenes integrates multiple categories into a single commercial and clinical ecosystem.
What makes RobGenes defensible.
Built assets and live commercial foundation.
From launch in August 2024 to a recurring $1.2M ARR run-rate with elite Middle East clinical partners.
Milestone-based fundraising.
Capital deployed to build enterprise value.
How investors may capture upside.
Investor upside may come from equity value growth as the company scales revenue, expands globally, validates verticals and becomes attractive to strategic acquirers or later-stage investors.
- ●Investment amount → ownership %
- ●Future dilution modeled
- ●Exit valuation scenarios
- ●Estimated MOIC & IRR
- ●Interactive simulator on Returns page
Multiple strategic exit pathways.
Visionary founder. Scientific authority.
Prof. Roberto Cammarata — Founder & CEO, RobGenes Holdings
A globally recognized authority in genomics, methylation, precision health and longevity medicine — uniting scientific depth with international commercial execution across the Middle East, Europe and Asia.
- ●Pioneer in clinical methylation interpretation
- ●Architect of the multi-omics RobGenes platform
- ●Trusted by tier-1 hospitals and longevity clinics
- ●Speaker, educator and physician trainer worldwide
- ●20+ years bridging molecular science and clinical practice
The window before scale.
RobGenes is at the stage where the platform vision, vertical structure and market opportunity are clear — but the largest enterprise value creation is still ahead.
- ●Early access to a multi-vertical precision health platform
- ●Strong market timing & live commercial traction
- ●Multiple recurring revenue streams
- ●Global expansion via licensing model
- ●AI-enhanced defensibility
- ●Potential for major valuation uplift as verticals commercialize
Request access to the private investor room.
Qualified investors, strategic partners, family offices, healthcare groups, laboratory networks and regional master license candidates may request access to private materials, financial models, vertical dashboards and investment discussions.